Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 1.00 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | UGCG | Q16739 | 1/20 | 0.35 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16408529 | 1.00 | SIGMAR1 (1.00) | SIGMAR1TMEM97SPHK2SPHK1NR1H4 | |
| SCHEMBL21870943 | 1.00 | SIGMAR1 (1.00) | SIGMAR1TMEM97SPHK2SPHK1NR1H4 | |
| SCHEMBL26665048 | 0.94 | SIGMAR1 (0.88) | SIGMAR1TMEM97CHRNB2CHRNA4GBA1 | |
| SCHEMBL26829074 | 0.94 | SIGMAR1 (0.88) | SIGMAR1TMEM97CHRNB2CHRNA4GBA1 | |
| SCHEMBL18100598 | 0.94 | SIGMAR1 (0.88) | SIGMAR1TMEM97CHRNB2CHRNA4GBA1 | |
| SCHEMBL30656608 | 0.94 | SIGMAR1 (0.88) | SIGMAR1TMEM97CHRNB2CHRNA4GBA1 | |
| SCHEMBL18099318 | 0.86 | SIGMAR1 (0.75) | SIGMAR1TMEM97NR1H4 | |
| SCHEMBL21499080 | 0.82 | SIGMAR1 (0.69) | SIGMAR1TMEM97 | |
| SCHEMBL18100596 | 0.82 | SIGMAR1 (0.69) | SIGMAR1TMEM97 | |
| SCHEMBL16408530 | 0.82 | SIGMAR1 (0.69) | SIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450275-B2 | Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450275-B2 | Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain | ELAVL1, ADH1A, NGF | SIGMAR1 423/4885TMEM97 1532/4885SPHK2 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.